Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Detecting and preventing reversion to toxicity for a formaldehyde-treated C. difficile toxin B mutant.

Wang B, Wang S, Rustandi RR, Wang F, Mensch CD, Hong L, Kristopeit A, Secore S, Dornadula G, Kanavage A, Heinrichs JH, Mach H, Blue JT, Thiriot DS.

Vaccine. 2015 Jan 1;33(1):252-9. doi: 10.1016/j.vaccine.2014.06.032. Epub 2014 Jun 18.

2.

Application of miniaturized immunoassays to discovery pharmacokinetic bioanalysis.

Roman J, Qiu J, Dornadula G, Hamuro L, Bakhtiar R, Verch T.

J Pharmacol Toxicol Methods. 2011 May-Jun;63(3):227-35. doi: 10.1016/j.vascn.2010.12.002. Epub 2010 Dec 13.

PMID:
21147239
3.

Potent and selective HIV-1 ribonuclease H inhibitors based on a 1-hydroxy-1,8-naphthyridin-2(1H)-one scaffold.

Williams PD, Staas DD, Venkatraman S, Loughran HM, Ruzek RD, Booth TM, Lyle TA, Wai JS, Vacca JP, Feuston BP, Ecto LT, Flynn JA, DiStefano DJ, Hazuda DJ, Bahnck CM, Himmelberger AL, Dornadula G, Hrin RC, Stillmock KA, Witmer MV, Miller MD, Grobler JA.

Bioorg Med Chem Lett. 2010 Nov 15;20(22):6754-7. doi: 10.1016/j.bmcl.2010.08.135. Epub 2010 Sep 24.

PMID:
20869872
4.

HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro.

Grobler JA, Dornadula G, Rice MR, Simcoe AL, Hazuda DJ, Miller MD.

J Biol Chem. 2007 Mar 16;282(11):8005-10. Epub 2006 Dec 15.

5.

Inhibition of endogenous reverse transcription of human and nonhuman primate lentiviruses: potential for development of lentivirucides.

Argyris EG, Dornadula G, Nunnari G, Acheampong E, Zhang C, Mehlman K, Pomerantz RJ, Zhang H.

Virology. 2006 Sep 30;353(2):482-90. Epub 2006 Jul 21.

6.
7.

Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques.

Hazuda DJ, Young SD, Guare JP, Anthony NJ, Gomez RP, Wai JS, Vacca JP, Handt L, Motzel SL, Klein HJ, Dornadula G, Danovich RM, Witmer MV, Wilson KA, Tussey L, Schleif WA, Gabryelski LS, Jin L, Miller MD, Casimiro DR, Emini EA, Shiver JW.

Science. 2004 Jul 23;305(5683):528-32. Epub 2004 Jul 8.

8.

Peripheral blood Dendritic cells are not a major reservoir for HIV type 1 in infected individuals on virally suppressive HAART.

Otero M, Nunnari G, Leto D, Sullivan J, Wang FX, Frank I, Xu Y, Patel C, Dornadula G, Kulkosky J, Pomerantz RJ.

AIDS Res Hum Retroviruses. 2003 Dec;19(12):1097-103.

PMID:
14709246
9.
10.

Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy.

Kulkosky J, Nunnari G, Otero M, Calarota S, Dornadula G, Zhang H, Malin A, Sullivan J, Xu Y, DeSimone J, Babinchak T, Stern J, Cavert W, Haase A, Pomerantz RJ.

J Infect Dis. 2002 Nov 15;186(10):1403-11. Epub 2002 Oct 29.

PMID:
12404155
11.

Residual HIV-1 disease in seminal cells of HIV-1-infected men on suppressive HAART: latency without on-going cellular infections.

Nunnari G, Otero M, Dornadula G, Vanella M, Zhang H, Frank I, Pomerantz RJ.

AIDS. 2002 Jan 4;16(1):39-45.

PMID:
11741161
12.

Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART.

Kulkosky J, Culnan DM, Roman J, Dornadula G, Schnell M, Boyd MR, Pomerantz RJ.

Blood. 2001 Nov 15;98(10):3006-15.

PMID:
11698284
13.

Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups.

Dornadula G, Nunnari G, Vanella M, Roman J, Babinchak T, DeSimone J, Stern J, Braffman M, Zhang H, Pomerantz RJ.

J Infect Dis. 2001 Jun 1;183(11):1682-7. Epub 2001 Apr 27.

PMID:
11343220
17.

Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy.

Dornadula G, Zhang H, VanUitert B, Stern J, Livornese L Jr, Ingerman MJ, Witek J, Kedanis RJ, Natkin J, DeSimone J, Pomerantz RJ.

JAMA. 1999 Nov 3;282(17):1627-32.

PMID:
10553788
18.

Natural endogenous reverse transcription of HIV-1.

Zhang H, Dornadula G, Pomerantz RJ.

J Reprod Immunol. 1998 Dec;41(1-2):255-60. Review.

PMID:
10213314
20.

Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy.

Zhang H, Dornadula G, Beumont M, Livornese L Jr, Van Uitert B, Henning K, Pomerantz RJ.

N Engl J Med. 1998 Dec 17;339(25):1803-9.

21.

Chemokine receptors and the molecular basis for human immunodeficiency virus type 1 entry into peripheral hematopoietic stem cells and their progeny.

Zhao SF, Li W, Dornadula G, Dicker D, Hoxie J, Peiper SC, Pomerantz RJ, Duan LX.

J Infect Dis. 1998 Dec;178(6):1623-34.

PMID:
9815214
22.

Viral burden and disease progression in HIV-1-infected patients with sickle cell anemia.

Bagasra O, Steiner RM, Ballas SK, Castro O, Dornadula G, Embury S, Jungkind D, Bobroski L, Kutlar A, Burchott S.

Am J Hematol. 1998 Nov;59(3):199-207.

23.

Natural endogenous reverse transcription of HIV type 1.

Zhang H, Dornadula G, Pomerantz RJ.

AIDS Res Hum Retroviruses. 1998 Apr;14 Suppl 1:S93-5.

PMID:
9581892
24.

Natural endogenous reverse transcription of simian immunodeficiency virus.

Dornadula G, Zhang H, Bagasra O, Pomerantz RJ.

Virology. 1997 Jan 6;227(1):260-7.

25.

Intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle by targeting human immunodeficiency virus type 1 integrase.

Levy-Mintz P, Duan L, Zhang H, Hu B, Dornadula G, Zhu M, Kulkosky J, Bizub-Bender D, Skalka AM, Pomerantz RJ.

J Virol. 1996 Dec;70(12):8821-32. Erratum in: J Virol 1998 Apr;72(4):3505-6. J Virol 2001 Jan;75(2):1092-3.

26.
27.

Mechanisms of transcriptional transactivation and restriction of human immunodeficiency virus type I replication in an astrocytic glial cell.

Niikura M, Dornadula G, Zhang H, Mukhtar M, Lingxun D, Khalili K, Bagasra O, Pomerantz RJ.

Oncogene. 1996 Jul 18;13(2):313-22.

PMID:
8710370

Supplemental Content

Loading ...
Support Center